{"ticker": {"uuid": "8030d90d-a424-439e-aa56-6d9def75c561", "symbol": "GALD", "name": "Galderma Group AG", "exchange": "VIE", "country": "AT", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Evaluating Galderma Group (SWX:GALD) After Dividend Approval And Board Refresh", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galderma stock rises after reporting strong Q1 sales led by US", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNbURkVWhLdm1KZ3BFa3M4ZnYxMVNFbHZTbW5vRUpVdVdMYTNhS19nMlFpOWhQY3dqWjhjM0pIeTFhSXo4T0VlTlZKQ2JETVB6ZDVsTGRKVVFSaTQ2bEZuR09wNTBJZGRYRFRxV2hnMUtmSlMyMWUtU0hGOEZhVGc3bmZMYkcxWTRWd2o0STFDb1hEX29YUUtMcXZxR2JlMUZJUnI3Y0tjbTA3aEVFaU1B?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Galderma Group (SWX:GALD) Valuation After Recent Share Price Resilience", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPZ3g1N3kyeVM4Vm4wYXRSQzQ5QkRVV2wtcndXaVV2b3JDRW4xZGJ1aWpGZ2l2ZTNtOG9hNVlvUW5LM29DZ0o5YzRpRW5sUGxaMFkzM3JCU1RIQWp4WDNMRjQ0YS1WNXd2QVU0MVF2LWpUUzU2cTBYRDNwYjhianYybW4zTVpnWkJqY1AzUmlwNUU2VWlzd2FKREJHWE1QSU0?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galderma investors sell $6.3 billion of stock in biggest deal of its kind", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQekNyT3JzWU5IOHpselVrei1SUWdtd0p4RDdPTFdLcVZ5Yl9MZU1MOURZellqbXBxblVfVXJKMG5zclFMT2xLdVhtWFRQRjN0cnBKTHh2blo0NTlFVWtsdzQ5X2gweDV5OWk2Nkl1dnFXSjVnSGZHbVYtVGhMckVNQkZUM3VBNHpnSUM0WkM5WS01Nm5qZVAtejNYblBYR2Q3U0lkSk1GeFF5OGVuU3MxUWFJeVlwc2pTUHlZVlV6MXVjOTlscngyWEpidmdfM0lRRlFCc0lrWFhtdw?oc=5", "source_name": "TradingView", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Galderma Group (SWX:GALD) Valuation After Record 2025 Results And Upgraded Nemluvio Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNaFBwRUVLM19oN0RPZW1PRk1BT3dDRzFaV1JoVnVnSmxxQ0xCR29nZl96aGt2dF9fNWhtVEVzVl9oTmpUTkhfc2o5TnF0NVdRRWoteUpUMi10VWg1MTROd2JTVS0xTWpueF9aUTZMd0ZtSy1WVkNfY291Q29zaGlHWkFCMElHQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is FDA\u2019s RelabotulinumtoxinA Filing Progress Altering The Investment Case For Galderma Group (SWX:GALD)?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late to Consider Galderma After Its 61% Surge in 2025?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQYTVkaDhZSlZ3ZVpGNW56cmdhdVFCVF9tUkViekRkdHk0MFFabTkta3dWMURBR2ZxeXd3alYtMmoxejdmUjg2MUtPWU9EQUFEQ0EyTDJmbjRVa0szc19RNW5iNm52WmFnZnFpZ3VyVUs3emRpclVoWnRUeTZKMTFBTk5B?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Galderma Group (VTX:GALD) A Risky Investment?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-24T07:00:00+00:00", "published_display": "24 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Individual investors own 13% of Galderma Group AG (VTX:GALD) shares but private equity firms control 58% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNaTg3SEdPaUJETEVSQ2tsUU1rUG51SUlRWjBMNERvUG95bHA3OEw2V0FFbHFKN3J6dVZFWEVJRHp2dnBneS1uQ2JlRThaNTU2UEZrODBSRkxxRU1pVEV6TE9sTkQ4SWNLQkNiU2tGeWxib3I5MmpqUHBidy1meXJpY3RwQkFIS1pOeEE?oc=5", "source_name": "Market source", "published_at": "2024-09-23T07:00:00+00:00", "published_display": "23 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Evaluating Galderma Group (SWX:GALD) After Dividend Approval And Board Refresh", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galderma stock rises after reporting strong Q1 sales led by US", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNbURkVWhLdm1KZ3BFa3M4ZnYxMVNFbHZTbW5vRUpVdVdMYTNhS19nMlFpOWhQY3dqWjhjM0pIeTFhSXo4T0VlTlZKQ2JETVB6ZDVsTGRKVVFSaTQ2bEZuR09wNTBJZGRYRFRxV2hnMUtmSlMyMWUtU0hGOEZhVGc3bmZMYkcxWTRWd2o0STFDb1hEX29YUUtMcXZxR2JlMUZJUnI3Y0tjbTA3aEVFaU1B?oc=5", "source_name": "Investing.com", "published_at": "2026-04-23T07:00:00+00:00", "published_display": "23 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Galderma Group (SWX:GALD) Valuation After Recent Share Price Resilience", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPZ3g1N3kyeVM4Vm4wYXRSQzQ5QkRVV2wtcndXaVV2b3JDRW4xZGJ1aWpGZ2l2ZTNtOG9hNVlvUW5LM29DZ0o5YzRpRW5sUGxaMFkzM3JCU1RIQWp4WDNMRjQ0YS1WNXd2QVU0MVF2LWpUUzU2cTBYRDNwYjhianYybW4zTVpnWkJqY1AzUmlwNUU2VWlzd2FKREJHWE1QSU0?oc=5", "source_name": "Market source", "published_at": "2026-03-26T07:00:00+00:00", "published_display": "26 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Galderma investors sell $6.3 billion of stock in biggest deal of its kind", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxQekNyT3JzWU5IOHpselVrei1SUWdtd0p4RDdPTFdLcVZ5Yl9MZU1MOURZellqbXBxblVfVXJKMG5zclFMT2xLdVhtWFRQRjN0cnBKTHh2blo0NTlFVWtsdzQ5X2gweDV5OWk2Nkl1dnFXSjVnSGZHbVYtVGhMckVNQkZUM3VBNHpnSUM0WkM5WS01Nm5qZVAtejNYblBYR2Q3U0lkSk1GeFF5OGVuU3MxUWFJeVlwc2pTUHlZVlV6MXVjOTlscngyWEpidmdfM0lRRlFCc0lrWFhtdw?oc=5", "source_name": "TradingView", "published_at": "2026-03-11T07:00:00+00:00", "published_display": "11 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Galderma Group (SWX:GALD) Valuation After Record 2025 Results And Upgraded Nemluvio Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNaFBwRUVLM19oN0RPZW1PRk1BT3dDRzFaV1JoVnVnSmxxQ0xCR29nZl96aGt2dF9fNWhtVEVzVl9oTmpUTkhfc2o5TnF0NVdRRWoteUpUMi10VWg1MTROd2JTVS0xTWpueF9aUTZMd0ZtSy1WVkNfY291Q29zaGlHWkFCMElHQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-08T08:00:00+00:00", "published_display": "08 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is FDA\u2019s RelabotulinumtoxinA Filing Progress Altering The Investment Case For Galderma Group (SWX:GALD)?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxNdnFteWN4Znpzc1NYWmp4YkV0RkRFRktISEZYZW9kQjRvdE5ja0RxY0RjREhMV1dZVEhqR1JBSElhU1pkWTR4eEtXOXRFbno4b2xjSG1OWnFYVnJmZ2FhdFZsazRpTkdhVWpBVjdJYkdzM0J0MXY0ejlHT1pGQ2tEb0NqNENJTmZsTmt2Ym1xeXNkQVRJLXlOYmxDTlFpcjZGcUhrNzE3NEI5NkxMNHlxaEIzVUQ1eUtqaTFQSUlnckV5bEM2LUhSRXNzVWNMOGpEd0pxLWFNMkxJTncxLXRnc2s4S3NZVVXSAewBQVVfeXFMTk5xNThfRmhxWlV6TUYzaUdYcWtnV2Q2dmFTQjFKNl9XTFhfV29DWU5HbkxoYy1tUHVNcmx5MlM0SVVza3J4TE8wU0hVUVhLaUJPSmkzY1JsNjNWWnJacFI2VGhXY00zcDhSYVFsUjRITFlWVEJ6Q05aX1NjNkJ6Q0luMTA3VTZGV0NzcERrNm1FWHhGcXo4LWZDN0VxckpVNWdodFhZYWQwdEsxanVmWndJcFBQYXQxdllpbl8wS3RpYTBNcEV0SjNpMTh5elh0WU1RSzl6RExLbmVnMllodi1QbV9nejFEMmZSLW4?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late to Consider Galderma After Its 61% Surge in 2025?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxQYTVkaDhZSlZ3ZVpGNW56cmdhdVFCVF9tUkViekRkdHk0MFFabTkta3dWMURBR2ZxeXd3alYtMmoxejdmUjg2MUtPWU9EQUFEQ0EyTDJmbjRVa0szc19RNW5iNm52WmFnZnFpZ3VyVUs3emRpclVoWnRUeTZKMTFBTk5B?oc=5", "source_name": "Market source", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Galderma Group (VTX:GALD) A Risky Investment?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-08-24T07:00:00+00:00", "published_display": "24 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Individual investors own 13% of Galderma Group AG (VTX:GALD) shares but private equity firms control 58% of the company", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxNaTg3SEdPaUJETEVSQ2tsUU1rUG51SUlRWjBMNERvUG95bHA3OEw2V0FFbHFKN3J6dVZFWEVJRHp2dnBneS1uQ2JlRThaNTU2UEZrODBSRkxxRU1pVEV6TE9sTkQ4SWNLQkNiU2tGeWxib3I5MmpqUHBidy1meXJpY3RwQkFIS1pOeEE?oc=5", "source_name": "Market source", "published_at": "2024-09-23T07:00:00+00:00", "published_display": "23 Sep 2024 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 44, "total_relevant": 9, "sentiment_summary": {"positive": 3, "negative": 1, "neutral": 5, "score": 54, "total": 9, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 3.3, "count": 6}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "earnings", "label": "Earnings", "weight": 0.55, "count": 1}], "positive_events": 3, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 187.0, "latest_week": "2026-06-12", "one_week_move": 6.2, "four_week_move": 10.7, "twelve_week_move": 20.1, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.701369, "market_dynamics_buy_signal": false, "relative_strength": null, "fair_value_gap": 11.0, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 41.0909, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+6.2% over one week, +10.7% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "Investing.com", "count": 1}, {"label": "TradingView", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 9}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 6}, {"label": "Capital return", "count": 1}, {"label": "Deals and strategy", "count": 1}, {"label": "Earnings", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "9", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+6.2% over one week, +10.7% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Evaluating Galderma Group (SWX:GALD) After Dividend Approval And Board Refresh"}], "updated_at": "2026-06-19T14:55:24.950132+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}